{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T03:07:22Z","timestamp":1768532842660,"version":"3.49.0"},"reference-count":10,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2018,11,2]],"date-time":"2018-11-02T00:00:00Z","timestamp":1541116800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,2,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Human epidermal growth factor receptor 2 (HER2)-targeted antibodies, including pertuzumab and trastuzumab, improve overall survival and progression-free survival among women with HER2-positive metastatic breast cancer, but grade \u22653 cardiotoxicity occurs in approximately 8% of cases. Here we report a case of Takotsubo cardiomyopathy associated with the use of dual anti-HER2 therapy in a 63-year-old woman who presented to the emergency department with an 8- to 10-hour history of progressive dyspnea after completing her third cycle of pertuzumab plus trastuzumab in addition to nab-paclitaxel chemotherapy. To our knowledge, this patient represents the first reported case of Takotsubo cardiomyopathy associated with pertuzumab plus trastuzumab combination therapy in the literature.<\/jats:p>","DOI":"10.1634\/theoncologist.2018-0285","type":"journal-article","created":{"date-parts":[[2018,11,2]],"date-time":"2018-11-02T13:54:46Z","timestamp":1541166886000},"page":"e80-e82","source":"Crossref","is-referenced-by-count":11,"title":["Takotsubo Cardiomyopathy During Anti-HER2 Therapy for Metastatic Breast Cancer"],"prefix":"10.1093","volume":"24","author":[{"given":"Caitlin","family":"Lees","sequence":"first","affiliation":[{"name":"Department of Medicine, Dalhousie University, Halifax, Nova Scotia, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Payam","family":"Yazdan-Ashoori","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Toronto, Toronto, Ontario, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katarzyna J.","family":"Jerzak","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Toronto, Toronto, Ontario, Canada"},{"name":"Sunnybrook Odette Cancer Centre, Toronto, Ontario, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sonal","family":"Gandhi","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Toronto, Toronto, Ontario, Canada"},{"name":"Sunnybrook Odette Cancer Centre, Toronto, Ontario, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2018,11,2]]},"reference":[{"key":"2021122506223983100_onco12712-bib-0001","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1634\/theoncologist.2012-0448","article-title":"Cardiac tolerability of pertuzumab plus trastuzumab plus docetaxel in patients with HER2-positive metastatic breast cancer in CLEOPATRA: A randomized, double-blind, placebo-controlled phase III study","volume":"18","author":"Swain","year":"2013","journal-title":"The Oncologist"},{"key":"2021122506223983100_onco12712-bib-0002","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1056\/NEJMoa1413513","article-title":"Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer","volume":"372","author":"Swain","year":"2015","journal-title":"N Engl J Med"},{"key":"2021122506223983100_onco12712-bib-0003","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1007\/s10549-012-2209-z","article-title":"Treatment patterns and clinical outcomes in elderly patients with HER2-positive metastatic breast cancer from the registHER observational study","volume":"135","author":"Kaufman","year":"2012","journal-title":"Breast Cancer Res Treat"},{"key":"2021122506223983100_onco12712-bib-0004","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/s11739-015-1362-x","article-title":"Risk of severe cardiotoxicity following treatment with trastuzumab: A meta-analysis of randomized and cohort studies of 29,000 women with breast cancer","volume":"11","author":"Mantarro","year":"2016","journal-title":"Intern Emerg Med"},{"key":"2021122506223983100_onco12712-bib-0005","doi-asserted-by":"crossref","first-page":"2080","DOI":"10.1074\/jbc.M804570200","article-title":"Blockade of the erbB2 receptor induces cardiomyocyte death through mitochondrial and reactive oxygen species-dependent pathways","volume":"284","author":"Gordon","year":"2009","journal-title":"J Biol Chem"},{"key":"2021122506223983100_onco12712-bib-0006","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1161\/CIRCULATIONAHA.107.690487","article-title":"Role of neuregulin-1\/ErbB signaling in cardiovascular physiology and disease: Implications for therapy of heart failure","volume":"116","author":"Lemmens","year":"2007","journal-title":"Circulation"},{"key":"2021122506223983100_onco12712-bib-0007","doi-asserted-by":"crossref","first-page":"214","DOI":"10.2174\/157340311799960645","article-title":"Anthracycline cardiotoxicity: Prevalence, pathogenesis and treatment","volume":"7","author":"Volkova","year":"2011","journal-title":"Curr Cardiol Rev"},{"key":"2021122506223983100_onco12712-bib-0008","doi-asserted-by":"crossref","first-page":"2284","DOI":"10.1016\/j.amjcard.2017.09.009","article-title":"Stress-induced cardiomyopathy in cancer patients","volume":"120","author":"Giza","year":"2017","journal-title":"Am J Cardiol"},{"issue":"8","key":"2021122506223983100_onco12712-bib-0009","first-page":"157","article-title":"The intriguing triangle of cancer, chemotherapy and takotsubo syndrome","author":"Madias","year":"2016","journal-title":"Oxford Med Case Reports"},{"key":"2021122506223983100_onco12712-bib-0010","doi-asserted-by":"crossref","first-page":"830","DOI":"10.7326\/0003-4819-152-12-201006150-00026","article-title":"Tako-tsubo (stress-induced) cardiomyopathy and cancer","volume":"152","author":"Burgdorf","year":"2010","journal-title":"Ann Intern Med"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1634\/theoncologist.2018-0285","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1634\/theoncologist.2018-0285","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/24\/2\/e80\/41917216\/oncolo_24_2_e80.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/24\/2\/e80\/41917216\/oncolo_24_2_e80.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,25]],"date-time":"2021-12-25T06:23:34Z","timestamp":1640413414000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/24\/2\/e80\/6439123"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11,2]]},"references-count":10,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2018,11,2]]},"published-print":{"date-parts":[[2019,2,1]]}},"URL":"https:\/\/doi.org\/10.1634\/theoncologist.2018-0285","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,2,1]]},"published":{"date-parts":[[2018,11,2]]}}}